Market Overview

The global genome editing market is undergoing a period of rapid transformation, driven by landmark scientific milestones, high-value industry collaborations, and a steady stream of regulatory breakthroughs. According to The Insight Partners, the market was valued at US$ 5,199.40 million in 2021 and is projected to reach US$ 16,986.69 million by 2028, at a strong CAGR of 18.4% over the 2022–2028 forecast period.

From CRISPR-based clinical trial advances to strategic acquisitions reshaping the competitive landscape, recent developments across the genome editing ecosystem signal an industry at an inflection point. These events are not only accelerating near-term market growth but are also laying the foundation for a new era of precision medicine, where genetic intervention becomes a mainstream therapeutic modality.

📥 Download  Sample PDF Report  https://www.theinsightpartners.com/sample/TIPHE100000853

Key Market Drivers Behind Recent Momentum

Several powerful structural forces are fueling the wave of recent activity in the genome editing market.

Escalating Cancer and Genetic Disease Burden continues to be the primary demand catalyst. The WHO recorded approximately 10 million cancer deaths in 2020, with global incidence rates still climbing. CRISPR/Cas9 systems have demonstrated strong efficacy against metastatic tumors, while chromosomal abnormalities present in roughly 1 in 150 live births  are creating sustained demand for gene-editing solutions across clinical and research settings.

AI-Powered CRISPR Innovation is fundamentally changing how genome editing tools are developed and deployed. Artificial intelligence is accelerating the design and optimization of CRISPR components, enabling researchers to predict off-target effects, improve editing efficiency, and develop next-generation delivery systems at unprecedented speed. This convergence of AI and genomics is one of the most consequential trends shaping market news today.

Strategic Partnerships and Acquisitions are rapidly reshaping the competitive landscape. Pharmaceutical giants and biotech innovators are forging multi-billion-dollar alliances to co-develop gene-editing therapies, acquire specialized capabilities, and expand geographic reach translating directly into accelerated product pipelines and faster time-to-market.

Regulatory Advancement and FDA Support is providing the commercial confidence that attracts continued investment. Progressive regulatory pathways, particularly in the United States, are validating gene therapy as a mainstream treatment category, encouraging both established players and emerging startups to accelerate clinical programs.

Recent Developments Shaping the Market

IDT Launches rhAmpSeq CRISPR Analysis System November 2021

Integrated DNA Technologies (IDT), a leading genomics solutions provider, launched its rhAmpSeq CRISPR Analysis System in November 2021. The system delivers an end-to-end solution for characterizing and quantifying both on-target and off-target genome editing events in CRISPR research projects. This launch represents a significant step forward in CRISPR quality assurance, addressing one of the field's most pressing technical challenges ensuring editing precision and minimizing unintended genomic alterations.

Editas Medicine Receives FDA IND Clearance for EDIT-301 December 2021

Editas Medicine announced in December 2021 that the US FDA cleared its Investigational New Drug (IND) application for EDIT-301, a CRISPR-based therapy targeting transfusion-dependent beta thalassemia (TDT). This clearance enables the company to initiate a Phase 1/2 clinical study, marking a pivotal milestone in the development of curative gene-editing therapies for serious blood disorders. EDIT-301 is also being explored for sickle cell disease, broadening its therapeutic potential considerably.

Horizon Discovery Expands CRISPR Screening Portfolio August 2020

Horizon Discovery Group announced the addition of single-cell RNA sequencing-linked pooled CRISPR screening to its service portfolio. This platform provides high-quality screening data and biological insight that address critical gaps in target identification and validation capabilities increasingly demanded by pharmaceutical companies seeking to build more robust and efficient drug discovery pipelines.

Eurofins Scientific Acquires Genetic Lab (G Lab) December 2021

Eurofins Scientific agreed to acquire Genetic Lab (G Lab), a Japan-based molecular biology testing services provider, from Transgenic Inc. G Lab specializes in molecular biology-based testing for diagnostics, biomarker development, and drug discovery. This acquisition strengthens Eurofins' footprint in Asia Pacific the fastest-growing genome editing market globally and enhances its capabilities in high-demand testing segments.

New England Biolabs Acquires Fluorogenics Limited May 2021

New England Biolabs entered into an agreement to acquire Fluorogenics Limited (FGL), a UK-based lyophilization R&D service company. FGL became a wholly owned subsidiary of NEB, enhancing the company's capabilities in reagent stability and delivery critical factors for expanding genome editing tools into broader clinical and field applications.

Eli Lilly and Precision BioSciences Partnership November 2020

One of the most financially significant recent developments, Eli Lilly partnered with Precision BioSciences to develop in vivo genome editing treatments for genetic disorders using the proprietary ARCUS platform. The collaboration is structured to generate up to USD 2.7 billion for Precision BioSciences, underscoring the enormous commercial value pharmaceutical companies place on best-in-class genome editing technologies.

Oxford Biomedica and Microsoft Research Collaboration

Oxford Biomedica plc partnered with Microsoft Research to leverage cloud computing and machine learning for advancing LentiVector gene therapy manufacturing. Using Microsoft's Azure intelligent cloud, the collaboration develops in silico models and algorithms to optimize next-generation cell and gene delivery a landmark example of the AI-genomics convergence driving the market's next wave of innovation.

FDA Approves Lumakras for KRAS-Mutant Lung Cancer May 2021

The FDA's approval of Lumakras (Sotorasib) in May 2021 for adult patients with KRAS G12C-mutant non-small cell lung cancer marked a watershed regulatory moment for genomically targeted therapies. While not a genome editing product itself, this approval validates the broader commercial and regulatory pathway for precision genetic medicine, reinforcing investor and industry confidence in the genome editing sector.

Top Market Players

The companies at the forefront of global genome editing market news and innovation include:

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Lonza
  • Horizon Discovery Group plc.
  • Integrated DNA Technologies (IDT)
  • GenScript
  • New England Biolabs
  • Eurofins Scientific
  • CRISPR Therapeutics
  • Editas Medicine

About Us

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, and Chemicals and Materials.

Related Riport:   genome editing market size

Contact Us

Also Available in :

Korean German Japanese French Chinese Italian Spanish